Johnson & Johnson's Rybrevant Faspro™ Shows 56% Response Rate in First-Line Head and Neck Cancer
- The Phase 1b/2 OrigAMI-4 study was presented at the 2026 Multidisciplinary Head and Neck Cancers Symposium.
- The study focuses on subcutaneous amivantamab and hyaluronidase-lpuj combined with a PD-1 inhibitor.
- The treatment targets EGFR and MET pathways to improve outcomes in head and neck squamous cell carcinoma.
Study Overview
The Phase 1b/2 OrigAMI-4 study, presented at the 2026 Multidisciplinary Head and Neck Cancers Symposium, investigates the efficacy of a new treatment combination for head and neck squamous cell carcinoma (HNSCC).
Treatment Details
The study examines the use of subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor. This approach targets key pathways involved in tumor growth and resistance, specifically epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET).
Clinical Significance
Current treatments for recurrent or metastatic HNSCC show limited effectiveness, with PD-1 monotherapy achieving response rates of around 18 percent. The new combination aims to provide more durable and meaningful antitumor activity.
Expert Insight
Dr. Ranee Mehra highlights the potential of this treatment to offer deeper responses compared to existing standards, emphasizing the importance of continued research to integrate this approach into first-line treatment strategies.
Source: J&J